Patents by Inventor Rolf Grempler

Rolf Grempler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 12115179
    Abstract: The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: October 15, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Christian Broedl, Rolf Grempler
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20240335514
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.
    Type: Application
    Filed: June 18, 2024
    Publication date: October 10, 2024
    Inventors: Rolf GREMPLER, Odd-Erik JOHANSEN, Thomas KLEIN, Gerd Roland LUIPPOLD, Michael MARK
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20230285432
    Abstract: The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: May 19, 2023
    Publication date: September 14, 2023
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli Christian BROEDL, Rolf GREMPLER
  • NEW ORAL PHARMACEUTICAL COMPOSITION FOR CANCER THERAPY
    Publication number: 20230058171
    Abstract: One aspect of the invention refers to an oral pharmaceutical composition comprising the MDM2-antagonist of formula I in a dose range of 30 mg to 45 mg for use in the treatment of cancer, wherein this oral pharmaceutical composition is administered in a treatment cycle of once every three weeks (D1 q3w), wherein this treatment cycle of once every three weeks (D1 q3w) may be repeated that many times as considered beneficial for the patient from a medical point of view. Another aspect of the invention refers to an MDM2-antagonist of formula I for use in the first line systemic treatment (primary treatment) of dedifferentiated liposarcoma. A further aspect of the invention refers to the use of the MDM2-antagonist of formula I for the manufacture of a medicament for the treatment of a p53-wildtype and non-MDM2-amplified form of cancer.
    Type: Application
    Filed: August 8, 2022
    Publication date: February 23, 2023
    Inventors: Mehdi Mourad LAHMAR, Junxian GENG, Rolf GREMPLER, Alejandro PEREZ-PITARCH, Maren ROHRBACHER
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20220313716
    Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: June 3, 2022
    Publication date: October 6, 2022
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli Christian BROEDL, Rolf GREMPLER
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20220152159
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.
    Type: Application
    Filed: August 12, 2021
    Publication date: May 19, 2022
    Inventors: Rolf GREMPLER, Odd-Erik JOHANSEN, Thomas KLEIN, Gerd LUIPPOLD, Michael MARK
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20210346415
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.
    Type: Application
    Filed: February 16, 2021
    Publication date: November 11, 2021
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli Christian BROEDL, Rolf GREMPLER
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20210283156
    Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: December 8, 2020
    Publication date: September 16, 2021
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli Christian BROEDL, Rolf GREMPLER
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20200397867
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.
    Type: Application
    Filed: March 18, 2020
    Publication date: December 24, 2020
    Inventors: Rolf GREMPLER, Odd-Erik JOHANSEN, Thomas KLEIN, Gerd LUIPPOLD, Michael MARK
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20200085851
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.
    Type: Application
    Filed: June 26, 2019
    Publication date: March 19, 2020
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli Christian BROEDL, Rolf GREMPLER
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20200069713
    Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: June 19, 2019
    Publication date: March 5, 2020
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli Christian BROEDL, Rolf GREMPLER
  • Pharmaceutical composition, methods for treating and uses thereof
    Patent number: 10406172
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: September 10, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Broedl, Rolf Grempler
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20180193427
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 12, 2018
    Inventors: Rolf GREMPLER, Odd-Erik JOHANSEN, Thomas KLEIN, Gerd LUIPPOLD, Michael MARK
  • Combination therapy
    Patent number: 10004747
    Abstract: The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: June 26, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Klein, Rolf Grempler, Michael Mark
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20170305952
    Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and a GLP-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: July 7, 2017
    Publication date: October 26, 2017
    Inventors: Thomas KLEIN, Rolf GREMPLER, Michael MARK
  • COMBINATION THERAPY
    Publication number: 20170151249
    Abstract: The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.
    Type: Application
    Filed: February 9, 2017
    Publication date: June 1, 2017
    Inventors: Thomas KLEIN, Rolf GREMPLER, Michael MARK
  • Combination therapy
    Patent number: 9603851
    Abstract: The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: March 28, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Klein, Rolf Grempler, Michael Mark
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20170020907
    Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli Christian BROEDL, Rolf GREMPLER
  • PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
    Publication number: 20160158264
    Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 9, 2016
    Inventors: Peter EICKELMANN, Michael MARK, Leo John SEMAN, Leo THOMAS, Uli Christian BROEDL, Rolf GREMPLER
  • COMBINATION THERAPY
    Publication number: 20160038500
    Abstract: The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.
    Type: Application
    Filed: October 2, 2015
    Publication date: February 11, 2016
    Inventors: Thomas KLEIN, Rolf GREMPLER, Michael MARK